Compare UGI & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGI | TWST |
|---|---|---|
| Founded | 1940 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.2B |
| IPO Year | 1994 | 2018 |
| Metric | UGI | TWST |
|---|---|---|
| Price | $36.60 | $174.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $44.00 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 147.20 | 63.89 |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $7,287,000,000.00 | $376,572,000.00 |
| Revenue This Year | $8.88 | $18.91 |
| Revenue Next Year | $2.27 | $15.07 |
| P/E Ratio | $11.89 | ★ N/A |
| Revenue Growth | 1.07 | ★ 20.32 |
| 52 Week Low | $31.62 | $23.30 |
| 52 Week High | $41.34 | $170.66 |
| Indicator | UGI | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 64.48 |
| Support Level | $36.75 | $39.81 |
| Resistance Level | $37.58 | N/A |
| Average True Range (ATR) | 0.59 | 8.81 |
| MACD | -0.24 | 1.70 |
| Stochastic Oscillator | 12.93 | 75.58 |
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.